24 December 2025 As Edwards secures another win against its rival, LSIPR talks to Siddharth Kusumakar—partner at Powell Gilbert and counsel for the winning party.
24 December 2025
23 December 2025
22 December 2025
19 December 2025
18 December 2025
Latest Features
Europe
The High Court’s ruling clarifies aspects of the SPC waiver but leaves unresolved questions relating to export-country rights and confidentiality, say Claire Phipps-Jones and Luke Norton of Bristows.
Americas
Companies that integrate data rights into their IP strategy with a holistic approach will lead in innovation while minimising risk, says Terri Shieh-Newton of Mintz.
Americas
In the complex world of bsAb patenting, counsel need to turn chefs to serve up success. Benjamin Pelletier of Haynes Boone puts together a menu of dos and don’ts.
Europe
With EU trilogues deadlocked over the package, the future of drug exclusivities and access-linked obligations hangs in the balance. Jackie Mulryne and Paul Ranson of Morgan Lewis pinpoint the flashpoints to watch as negotiators push for a year-end deal.
Big Pharma
Clinical trials create a patent paradox. With EPO case law rapidly reshaping the 'expectation of success' test—most recently T136/24—the line between innovation and obviousness is blurred. Amanda Simons of J A Kemp offers drafting strategies to secure protection for your downstream innovations.
Americas
The USPTO’s ‘settled expectations’ rule is anything but settled, argues Andrew Zappia of Troutman Pepper Locke.
Americas
Parties impacted by exclusion orders need to carefully weigh their options for seeking clarity or rulings on redesigns, explain Daniel Muino and Charles Provine from Morrison Foerster.
Europe
As Big Pharma stalls investment in the UK, the government urgently needs to return to the negotiating table to salvage a key growth area, writes Tim Belcher of EIP.
Latest Conference Videos
Americas
Speakers from Greenberg Traurig, Verdiva Bio, Halozyme, and Metsera discuss the implications of the USPTO’s 2024 §112 guidelines on life sciences patents.
Europe
Amanda Simons, J A Kemp, explains how clinical research affects patentability in Europe and how clinical data can be used to strengthen protection.
Biotechnology
Dirk Buehler, Maiwald, discusses how the “try and see” standard is applied before the EPO and its relevance in pharma and biotech cases.
Europe
High-value IP disputes are reshaping life sciences litigation, with perspectives from McDermott Will & Emery, Curevac, Regeneron, HGF, and the UPC.
More News
17 December 2025 The proponents of a petition denied by the Supreme Court said it addressed a conflict that was significant “not just for the pharmaceutical industry, but for all stakeholders in our patent system”.
17 December 2025 The firm’s new hire is known for advising Boston’s biotech, pharmaceutical and chemical companies on patent strategies and commercialising scientific inventions.
16 December 2025 UK court hears claims that a delay and construction inconsistency led to the alleged wrongful invalidation of a patent at the heart of a global dispute.
15 December 2025 The proposed 1,400-strong firm will combine Taylor Wessing's top UK and European practice with Winston & Strawn's US-focused IP litigation team.
15 December 2025 The country aims to become the world’s third-largest life sciences economy by 2035, but stalled investments, regulatory hurdles, and talent shortages are raising questions about whether the target is achievable, finds Marisa Woutersen.
11 December 2025 Israeli drug maker bows to FTC pressure, removing scores of “improperly listed” patents in boon for generic manufacturers.
11 December 2025 The lateral hire from Covington & Burling will strengthen the firm's cross-border expertise as the UK and EU markets ‘navigate regulatory and technological shifts’, said the firm.
Get up-to-date information on all our publications and events
Get critical life sciences news direct to your inbox